Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

Prodigiosin, a bioactive secondary metabolite produced by , is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in bioengineering and biotechnology 2020-05, Vol.8, p.424
Main Authors: Guryanov, Ivan, Naumenko, Ekaterina, Akhatova, Farida, Lazzara, Giuseppe, Cavallaro, Giuseppe, Nigamatzyanova, Läysän, Fakhrullin, Rawil
Format: Article
Language:English
Subjects:
anti-cancer drugs
Bioengineering and Biotechnology
cancer
comet assay
drug delivery
genotoxic effect
halloysite nanotubes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prodigiosin, a bioactive secondary metabolite produced by , is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelial colorectal adenocarcinoma (Caco-2) and human colon carcinoma (HCT116) cells proliferative activity. After treatment of Caco-2 cells with prodigiosin-loaded halloysite nanotubes, we have observed a disorganization of the F-actin structure. Comparison of this effects on malignant (Caco-2, HCT116) and non-malignant (MSC, HSF) cells suggests the selective cytotoxic and genotoxic activity of prodigiosin-HNTs nanoformulation.
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2020.00424